Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

A prostate cancer diagnosis can feel overwhelming, but the growing number of targeted treatments means patients (and their ...

Pluvicto is currently approved for metastatic castration-resistant prostate cancer (mCRPC). Given that nearly all mHSPC patients eventually progress to mCRPC, these new data suggest its potential ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

"These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...